Horizon Pharma (HZNP) Enters Commercialization License for DUEXIS in LatAm
Tweet Send to a FriendGet Alerts HZNP Hot Sheet
Up)
Trade HZNP Now!
Horizon Pharma, Inc. (NASDAQ: HZNP) has entered into an exclusive agreement with Grunenthal for the commercialization of DUEXIS in Latin America.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Oncolytics Biotech (ONCY) REOLYSIN w/ REO 020 Met Primary Endpoint in Phase 2
- Pandora (P) Gets Even More Social with New Facebook (FB) Timeline App
- Salix Pharma (SLXP) Reports Positive Results From Two Budesonide Foam Phase 3s
Create E-mail Alert Related Categories
Corporate News, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
